+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Knockdown Service Market - Global Forecast 2026-2032- Product Image
Gene Knockdown Service Market - Global Forecast 2026-2032- Product Image
Sale

Gene Knockdown Service Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6140055
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gene Knockdown Service Market is projected to reach USD 8.46 Billion in 2026. It is expected to continue growing at a CAGR of 8.71%, reaching USD 13.94 Billion by 2032.

Gene Knockdown Services: Executive Overview

Gene knockdown services support life-science research by reducing the expression of selected genes through approaches such as RNA interference, antisense oligonucleotides, and related molecular tools. Demand is linked to functional genomics, target validation, disease-model development, drug discovery, and increasingly complex biological questions requiring reproducible and well-characterized experiments.

From Basic Silencing to Integrated Functional Genomics

The landscape is shifting from one-off gene-silencing experiments toward integrated workflows that combine design, delivery, validation, phenotypic analysis, and data interpretation. Researchers increasingly prioritize knockdown efficiency, specificity, durability, reproducibility across cell types, and compatibility with difficult biological models. Standardized controls, orthogonal validation, and transparent reporting are becoming important safeguards against misleading biological conclusions.

Artificial Intelligence Strengthens Design and Interpretation

Artificial intelligence is influencing gene knockdown services through sequence-design optimization, prediction of off-target effects, selection of delivery conditions, image-based phenotyping, and prioritization of experimental combinations. Its value depends on the quality and diversity of training data, experimental validation, and clear documentation of model limitations. The most practical applications combine computational ranking with laboratory confirmation rather than treating algorithmic predictions as definitive evidence.

Regional Dynamics Across Research and Biomanufacturing Ecosystems

North America benefits from strong biomedical research infrastructure, extensive translational activity, and demand for specialized outsourcing. Europe combines established academic and pharmaceutical capabilities with rigorous expectations for data governance and experimental quality. Asia-Pacific is supported by expanding research capacity, growing biotechnology activity, and increasing adoption of outsourced molecular services. Latin America is developing through university, clinical-research, and biotechnology networks, while the Middle East is strengthening life-science capabilities through institutional investment. Africa remains more unevenly developed, with opportunities tied to research infrastructure, infectious-disease studies, and partnerships that improve access to advanced molecular platforms.

Group-Level Priorities Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents a diverse set of research environments, with demand shaped by expanding biomedical capacity and cross-border collaboration. BRICS economies contribute substantial scientific diversity and emphasize domestic capability, translational research, and cost-conscious access. The European Union places particular weight on regulatory alignment, data protection, and reproducibility. G7 members generally support advanced research programs, specialized service procurement, and rigorous validation practices. GCC countries are building life-science ecosystems through strategic investment and international collaboration, while NATO members reflect varied national capabilities but share interests in biotechnology resilience, secure research infrastructure, and preparedness-related science.

Country-Level Research and Service Considerations

The United States and Canada combine mature research ecosystems with broad use of outsourced functional-genomics services. The United Kingdom, Germany, France, Italy, and Spain support active academic, clinical, and pharmaceutical research, with strong attention to quality systems and responsible data handling. China, Japan, South Korea, India, and Australia contribute growing or highly developed capabilities across molecular biology, translational research, and biotechnology. Brazil, Mexico, and Russia present distinct research environments shaped by national funding, institutional capacity, procurement conditions, and collaboration patterns. Across these countries, service selection increasingly depends on validated protocols, model-specific expertise, turnaround reliability, and the ability to provide complete experimental documentation.

Practical Priorities for Leaders Building Reliable Knockdown Workflows

Industry leaders should define success criteria before project initiation, including acceptable residual expression, assay endpoints, controls, and reproducibility requirements. They should favor providers that disclose sequence rationale, delivery methods, validation procedures, and known limitations. Multi-target or orthogonal confirmation can reduce the risk of sequence-specific artifacts, while pilot studies help identify cell-type and dose-related constraints. Investments in automation, secure data exchange, AI-assisted design with laboratory verification, and standardized quality documentation can improve cycle times without weakening scientific rigor.

Methodology for a Data-Grounded Executive Assessment

This executive assessment interprets the gene knockdown service category through established applications, technology characteristics, research workflows, and publicly observable life-science ecosystem conditions. It uses a qualitative synthesis of functional-genomics practices, molecular-biology service requirements, regional research capacity, and common procurement considerations. The assessment intentionally excludes market estimates, market shares, forecasts, company comparisons, and unsupported quantitative claims. Regional, group, and country observations are framed as contextual insights rather than measurements of commercial performance.

Conclusion: Quality, Validation, and Integration Define Progress

Gene knockdown services are becoming an important component of functional-genomics and translational research workflows. Competitive differentiation increasingly rests on experimental reliability, model-specific expertise, transparent validation, and the integration of computational tools with laboratory evidence. Organizations that treat knockdown as a complete, quality-controlled workflow-rather than a simple reagent purchase-will be better positioned to generate interpretable findings across diverse research settings.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gene Knockdown Service Market, by Product Type
7.1. Introduction
7.2. Antisense Oligonucleotide
7.2.1. Gapmers
7.2.2. Steric Blockers
7.3. MicroRNA
7.3.1. Inhibitor
7.3.2. Mimic
7.4. ShRNA
7.4.1. Lentiviral Vector
7.4.2. Plasmid Vector
7.5. SiRNA
7.5.1. Chemically Modified
7.5.2. Unmodified
8. Gene Knockdown Service Market, by Delivery Method
8.1. Introduction
8.2. Electroporation
8.2.1. Bulk Electroporation
8.2.2. Microfluidic Electroporation
8.3. Lipid-Based Transfection
8.3.1. Cationic Lipids
8.3.2. Ionizable Lipids
8.3.3. Peptide Formulations
8.4. Nanoparticle-Based Delivery
8.5. Viral Vector
8.5.1. Adeno-Associated Virus
8.5.2. Adenovirus
8.5.3. Lentivirus
9. Gene Knockdown Service Market, by End User
9.1. Introduction
9.2. Academic Research Institutes
9.2.1. Research Centers
9.2.2. Universities
9.3. Biotechnology Companies
9.3.1. Established Biotechnology
9.3.2. Start-Up Biotechnology
9.4. Contract Research Organizations
9.4.1. Global CROs
9.4.2. Regional CROs
9.5. Pharmaceutical Companies
9.5.1. Large Pharmaceutical
9.5.2. Mid-Size Pharmaceutical
10. Gene Knockdown Service Market, by Application
10.1. Introduction
10.2. Biomarker Validation
10.2.1. Diagnostic Markers
10.2.2. Prognostic Markers
10.3. Drug Discovery
10.3.1. Lead Optimization
10.3.2. Target Validation
10.4. Functional Genomics
10.4.1. Expression Profiling
10.4.2. Gene Function Analysis
10.5. Therapeutic Development
10.5.1. Clinical Trials
10.5.2. Preclinical Studies
11. Gene Knockdown Service Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiovascular Diseases
11.2.1. Atherosclerosis
11.2.2. Heart Failure
11.3. Infectious Diseases
11.3.1. Bacterial Infections
11.3.2. Viral Infections
11.4. Neurology
11.4.1. Alzheimer's Disease
11.4.2. Parkinson's Disease
11.5. Oncology
11.5.1. Breast Cancer
11.5.2. Leukemia
11.5.3. Lung Cancer
12. Gene Knockdown Service Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Gene Knockdown Service Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Gene Knockdown Service Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Agilent Technologies Inc
16.2. Altogen Labs Inc
16.3. BPS Bioscience Inc
16.4. CD Genomics Inc
16.5. Cellecta Inc
16.6. Charles River Laboratories International Inc
16.7. Creative Bioarray Inc
16.8. Creative Biogene Inc
16.9. Cyagen Biosciences Inc
16.10. Eurofins Scientific SE
16.11. GenScript Biotech Corporation
16.12. Horizon Discovery Group plc
16.13. Integrated DNA Technologies Inc
16.14. Lonza Group AG
16.15. Mirimus Inc
16.16. OriGene Technologies Inc
16.17. Runtogen Inc
16.18. Synthego Corporation
16.19. Takara Bio Inc
16.20. Thermo Fisher Scientific Inc
16.21. Ubigene Co Ltd
16.22. VectorBuilder Inc
16.23. WuXi AppTec Co Ltd
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gene Knockdown Service Market, Years Considered for the Study
FIGURE 2. Global Gene Knockdown Service Market, Research Design
FIGURE 3. Global Gene Knockdown Service Market, Research Framework
FIGURE 4. Global Gene Knockdown Service Market, Data Triangulation
FIGURE 5. Global Gene Knockdown Service Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gene Knockdown Service Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Gene Knockdown Service Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gene Knockdown Service Market Size, by Delivery Method, 2025 vs 2032 (%)
FIGURE 9. Global Gene Knockdown Service Market Size, by Delivery Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gene Knockdown Service Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Gene Knockdown Service Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gene Knockdown Service Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Gene Knockdown Service Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gene Knockdown Service Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 15. Global Gene Knockdown Service Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gene Knockdown Service Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Gene Knockdown Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gene Knockdown Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Gene Knockdown Service Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Gene Knockdown Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gene Knockdown Service Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gene Knockdown Service Market Segmentation & Coverage
TABLE 2. Global Gene Knockdown Service Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotide Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotide Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotide Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gapmers Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gapmers Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gapmers Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Steric Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Steric Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Steric Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global MicroRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global MicroRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global MicroRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Mimic Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Mimic Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Mimic Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global ShRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global ShRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global ShRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Lentiviral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Lentiviral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Lentiviral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Plasmid Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Plasmid Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Plasmid Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Chemically Modified Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Chemically Modified Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Chemically Modified Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Unmodified Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Unmodified Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Unmodified Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 41. Global Electroporation Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Electroporation Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Electroporation Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Bulk Electroporation Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Bulk Electroporation Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Bulk Electroporation Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Microfluidic Electroporation Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Microfluidic Electroporation Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Microfluidic Electroporation Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Lipid-Based Transfection Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Lipid-Based Transfection Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Lipid-Based Transfection Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Cationic Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Cationic Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Cationic Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Ionizable Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Ionizable Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Ionizable Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Peptide Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Peptide Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Peptide Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Nanoparticle-Based Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Nanoparticle-Based Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Nanoparticle-Based Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Adeno-Associated Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Adeno-Associated Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Adeno-Associated Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Adenovirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Adenovirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Adenovirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Lentivirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Lentivirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Lentivirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Research Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Research Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Research Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Universities Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Universities Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Universities Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Established Biotechnology Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Established Biotechnology Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Established Biotechnology Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Start-Up Biotechnology Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Start-Up Biotechnology Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Start-Up Biotechnology Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Global CROs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Global CROs Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Global CROs Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Regional CROs Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Regional CROs Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Regional CROs Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Large Pharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Large Pharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Large Pharmaceutical Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Mid-Size Pharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Mid-Size Pharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Mid-Size Pharmaceutical Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. Global Biomarker Validation Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Biomarker Validation Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Biomarker Validation Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Diagnostic Markers Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Diagnostic Markers Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Diagnostic Markers Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Prognostic Markers Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Prognostic Markers Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Prognostic Markers Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Drug Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Drug Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Drug Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Lead Optimization Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Lead Optimization Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Lead Optimization Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Target Validation Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Target Validation Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Target Validation Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Functional Genomics Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Functional Genomics Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Functional Genomics Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Expression Profiling Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Expression Profiling Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Expression Profiling Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Gene Function Analysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Gene Function Analysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Gene Function Analysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Therapeutic Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Therapeutic Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Therapeutic Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Clinical Trials Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global Clinical Trials Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global Clinical Trials Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global Preclinical Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Preclinical Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Preclinical Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 152. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Atherosclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Global Atherosclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. Global Atherosclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 158. Global Heart Failure Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Global Heart Failure Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. Global Heart Failure Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 180. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 188. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 189. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 191. Global Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 192. Asia-Pacific Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Asia-Pacific Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. Asia-Pacific Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 195. Asia-Pacific Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 196. Asia-Pacific Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 197. Asia-Pacific Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 198. Asia-Pacific Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 199. Asia-Pacific Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 200. Asia-Pacific Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 201. Asia-Pacific Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 202. Asia-Pacific Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Asia-Pacific Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 204. Asia-Pacific Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 205. Asia-Pacific Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 206. Asia-Pacific Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 207. Asia-Pacific Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 208. Asia-Pacific Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 209. Asia-Pacific Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 210. Asia-Pacific Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 211. Asia-Pacific Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 212. Asia-Pacific Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 213. Asia-Pacific Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 214. Asia-Pacific Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 215. Asia-Pacific Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 216. Asia-Pacific Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 217. North America Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 218. North America Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. North America Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 220. North America Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 221. North America Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 222. North America Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 223. North America Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 224. North America Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 225. North America Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 226. North America Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 227. North America Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. North America Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 229. North America Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 230. North America Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 231. North America Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 232. North America Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 233. North America Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 234. North America Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 235. North America Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 236. North America Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 237. North America Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 238. North America Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 239. North America Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 240. North America Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 241. North America Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 242. Latin America Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 243. Latin America Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 244. Latin America Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 245. Latin America Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 246. Latin America Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 247. Latin America Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 248. Latin America Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 249. Latin America Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 250. Latin America Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 251. Latin America Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 252. Latin America Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Latin America Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 254. Latin America Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 255. Latin America Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 256. Latin America Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 257. Latin America Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 258. Latin America Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 259. Latin America Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 260. Latin America Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 261. Latin America Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 262. Latin America Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 263. Latin America Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 264. Latin America Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 265. Latin America Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 266. Latin America Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 267. Europe Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 268. Europe Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Europe Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 270. Europe Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 271. Europe Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 272. Europe Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 273. Europe Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 274. Europe Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 275. Europe Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 276. Europe Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 277. Europe Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 278. Europe Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 279. Europe Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 280. Europe Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 281. Europe Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 282. Europe Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. Europe Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 284. Europe Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 285. Europe Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 286. Europe Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 287. Europe Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 288. Europe Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 289. Europe Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 290. Europe Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 291. Europe Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 292. Middle East Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 293. Middle East Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 294. Middle East Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 295. Middle East Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 296. Middle East Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 297. Middle East Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 298. Middle East Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 299. Middle East Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 300. Middle East Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 301. Middle East Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 302. Middle East Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. Middle East Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 304. Middle East Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 305. Middle East Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 306. Middle East Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 307. Middle East Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 308. Middle East Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 309. Middle East Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 310. Middle East Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 311. Middle East Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 312. Middle East Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 313. Middle East Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 314. Middle East Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 315. Middle East Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 316. Middle East Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 317. Africa Gene Knockdown Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 318. Africa Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 319. Africa Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 320. Africa Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 321. Africa Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 322. Africa Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 323. Africa Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 324. Africa Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 325. Africa Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 326. Africa Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 327. Africa Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 328. Africa Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 329. Africa Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
TABLE 330. Africa Gene Knockdown Service Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 331. Africa Gene Knockdown Service Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 332. Africa Gene Knockdown Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 333. Africa Gene Knockdown Service Market Size, by Biomarker Validation, 2017-2032 (USD Million)
TABLE 334. Africa Gene Knockdown Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 335. Africa Gene Knockdown Service Market Size, by Functional Genomics, 2017-2032 (USD Million)
TABLE 336. Africa Gene Knockdown Service Market Size, by Therapeutic Development, 2017-2032 (USD Million)
TABLE 337. Africa Gene Knockdown Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 338. Africa Gene Knockdown Service Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 339. Africa Gene Knockdown Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 340. Africa Gene Knockdown Service Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 341. Africa Gene Knockdown Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 342. Global Gene Knockdown Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 343. ASEAN Gene Knockdown Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 344. ASEAN Gene Knockdown Service Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 345. ASEAN Gene Knockdown Service Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 346. ASEAN Gene Knockdown Service Market Size, by MicroRNA, 2017-2032 (USD Million)
TABLE 347. ASEAN Gene Knockdown Service Market Size, by ShRNA, 2017-2032 (USD Million)
TABLE 348. ASEAN Gene Knockdown Service Market Size, by SiRNA, 2017-2032 (USD Million)
TABLE 349. ASEAN Gene Knockdown Service Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 350. ASEAN Gene Knockdown Service Market Size, by Electroporation, 2017-2032 (USD Million)
TABLE 351. ASEAN Gene Knockdown Service Market Size, by Lipid-Based Transfection, 2017-2032 (USD Million)
TABLE 352. ASEAN Gene Knockdown Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 353. ASEAN Gene Knockdown Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 354. ASEAN Gene Knockdown Service Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
TABLE 355. ASEAN Gene Knockdown Service Market Size, by Biotechnology Companies, 2017-2032 (USD Million)
T

Companies Mentioned

  • Agilent Technologies Inc
  • Altogen Labs Inc
  • BPS Bioscience Inc
  • CD Genomics Inc
  • Cellecta Inc
  • Charles River Laboratories International Inc
  • Creative Bioarray Inc
  • Creative Biogene Inc
  • Cyagen Biosciences Inc
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • Horizon Discovery Group plc
  • Integrated DNA Technologies Inc
  • Lonza Group AG
  • Mirimus Inc
  • OriGene Technologies Inc
  • Runtogen Inc
  • Synthego Corporation
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc
  • Ubigene Co Ltd
  • VectorBuilder Inc
  • WuXi AppTec Co Ltd

Related Topics

Related Reports

Gene Knockdown Stable Cell Line Service Market - Global Forecast 2026-2032 - Product Image

Gene Knockdown Stable Cell Line Service Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
RNAi Technology - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

RNAi Technology - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
RNAi Drug Delivery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

RNAi Drug Delivery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
shRNA Clone Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

shRNA Clone Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 208 Pages
  • Global
From
Antisense and RNAi Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Antisense and RNAi Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 108 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.